• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

急性肝性卟啉症(AHPs)的发病机制和临床特征。

Pathogenesis and clinical features of the acute hepatic porphyrias (AHPs).

机构信息

Section on Gastroenterology & Hepatology, and Molecular Medicine & Translational Science, Wake Forest University School of Medicine/NC Baptist Hospital, Winston-Salem, NC 27157, United States of America.

Section on Hematology & Oncology, Wake Forest University School of Medicine/NC Baptist Hospital, Winston-Salem, NC 27157, United States of America.

出版信息

Mol Genet Metab. 2019 Nov;128(3):213-218. doi: 10.1016/j.ymgme.2019.03.002. Epub 2019 Mar 6.

DOI:10.1016/j.ymgme.2019.03.002
PMID:30987916
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6754303/
Abstract

The acute hepatic porphyrias include four disorders: acute intermittent porphyria [AIP], hereditary coproporphyria [HCP], variegate porphyria [VP], and the rare porphyria due to severe deficiency of ALA dehydratase [ADP]. In the USA, AIP is the most severe and most often symptomatic. AIP, HCP, and VP are due to autosomal dominant genetic abnormalities, in which missense, nonsense, or other mutations of genes of normal hepatic heme biosynthesis, in concert with other environmental, nutritional, hormonal and genetic factors, may lead to a critical deficiency of heme, the end-product of the pathway, in a small but critical 'regulatory pool' within hepatocytes. This deficiency leads to de-repression of the first and normally rate-controlling enzyme of the heme synthetic pathway, delta- or 5-aminolevulinic acid [ALA] synthase-1, and thus to marked up-regulation of this key enzyme and to marked hepatic overproduction of ALA. In addition, except for ADP, there is marked overproduction as well of porphobilinogen [PBG], the intermediate immediately downstream of ALA in the synthetic chain, and, especially in HCP and VP, also porphyrinogens and porphyrins farther down the pathway. The major clinical features of the acute porphyrias are attacks of severe neuropathic-type pain. Pain is felt first and foremost in the abdomen but may also occur in the back, chest, and extremities. Attacks are more common in women than in men [ratio of about 4:1], often accompanied by nausea, vomiting, constipation, tachycardia, and arterial hypertension. Hyponatremia may also occur. Some patients also describe chronic symptoms of pain, anxiety, insomnia, and others.

摘要

急性肝卟啉症包括四种疾病

急性间歇性卟啉症(AIP)、遗传性粪卟啉症(HCP)、变异性卟啉症(VP)和罕见的由于严重缺乏 ALA 脱水酶(ADP)引起的卟啉症。在美国,AIP 是最严重和最常出现症状的。AIP、HCP 和 VP 是由于常染色体显性遗传异常引起的,其中错义、无义或其他突变正常肝血红素生物合成基因,与其他环境、营养、激素和遗传因素一起,可能导致在肝细胞内一个小但关键的“调节池”中血红素(该途径的终产物)严重缺乏。这种缺乏导致血红素合成途径的第一个和正常限速酶δ-或 5-氨基酮戊酸[ALA]合酶-1 的去阻遏,从而导致该关键酶的显著上调和 ALA 在肝脏中的大量产生。此外,除了 ADP 之外,还有明显的卟胆原[PBG]产生过多,PBG 是合成链中 ALA 的下游中间产物,特别是在 HCP 和 VP 中,还有卟啉原和更远的途径中的卟啉。急性卟啉症的主要临床特征是严重的神经型疼痛发作。疼痛首先和最主要地发生在腹部,但也可能发生在背部、胸部和四肢。发作在女性中比在男性中更常见[比例约为 4:1],常伴有恶心、呕吐、便秘、心动过速和动脉高血压。低钠血症也可能发生。一些患者还描述了慢性疼痛、焦虑、失眠等症状。

相似文献

1
Pathogenesis and clinical features of the acute hepatic porphyrias (AHPs).急性肝性卟啉症(AHPs)的发病机制和临床特征。
Mol Genet Metab. 2019 Nov;128(3):213-218. doi: 10.1016/j.ymgme.2019.03.002. Epub 2019 Mar 6.
2
AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review.AGA 临床实践更新:急性肝性血卟啉症的诊断和管理:专家综述。
Gastroenterology. 2023 Mar;164(3):484-491. doi: 10.1053/j.gastro.2022.11.034. Epub 2023 Jan 13.
3
Recent advances on porphyria genetics: Inheritance, penetrance & molecular heterogeneity, including new modifying/causative genes.卟啉症遗传学的最新进展:遗传、外显率和分子异质性,包括新的修饰/致病基因。
Mol Genet Metab. 2019 Nov;128(3):320-331. doi: 10.1016/j.ymgme.2018.11.012. Epub 2018 Nov 30.
4
5-Aminolevulinate dehydratase porphyria: Update on hepatic 5-aminolevulinic acid synthase induction and long-term response to hemin.δ-氨基酮戊酸脱水酶卟啉症:肝 5-氨基酮戊酸合酶诱导的最新进展及对血红素的长期反应
Mol Genet Metab. 2020 Dec;131(4):418-423. doi: 10.1016/j.ymgme.2020.10.011. Epub 2020 Oct 26.
5
Human hereditary hepatic porphyrias.人类遗传性肝卟啉症。
Clin Chim Acta. 2002 Nov;325(1-2):17-37. doi: 10.1016/s0009-8981(02)00276-0.
6
Murine models of the human porphyrias: Contributions toward understanding disease pathogenesis and the development of new therapies.人类卟啉症的鼠模型:对疾病发病机制的理解和新疗法的发展的贡献。
Mol Genet Metab. 2019 Nov;128(3):332-341. doi: 10.1016/j.ymgme.2019.01.007. Epub 2019 Jan 18.
7
ALAD Inhibition by Porphobilinogen Rationalizes the Accumulation of δ-Aminolevulinate in Acute Porphyrias.卟啉原脱氨酶抑制作用可解释急性卟啉病中 δ-氨基酮戊酸的积累。
Biochemistry. 2022 Nov 1;61(21):2409-2416. doi: 10.1021/acs.biochem.2c00434. Epub 2022 Oct 14.
8
Acute hepatic porphyrias: Identification of 46 hydroxymethylbilane synthase, 11 coproporphyrinogen oxidase, and 20 protoporphyrinogen oxidase novel mutations.急性肝卟啉症:鉴定 46 羟甲基胆素合酶、11 粪卟啉原氧化酶和 20 原卟啉原氧化酶的 46 种新突变。
Mol Genet Metab. 2019 Nov;128(3):352-357. doi: 10.1016/j.ymgme.2018.10.008. Epub 2018 Oct 26.
9
Heme biosynthesis and the porphyrias.血红素生物合成与卟啉病。
Mol Genet Metab. 2019 Nov;128(3):164-177. doi: 10.1016/j.ymgme.2019.04.008. Epub 2019 Apr 22.
10
Acute Intermittent Porphyria急性间歇性卟啉病

引用本文的文献

1
Practical Recommendations in the Treatment of Acute and Chronic Life-Threatening Infectious Diseases in Patients with Acute Hepatic Porphyria.急性肝卟啉病患者急慢性危及生命的传染病治疗实用建议
Metabolites. 2025 Feb 5;15(2):99. doi: 10.3390/metabo15020099.
2
A novel acquired resistance mechanism to 5-aminolevulinic acid-mediated photodynamic therapy with ABCG2 inhibition.一种通过抑制ABCG2产生的对5-氨基酮戊酸介导的光动力疗法的新型获得性耐药机制。
Photochem Photobiol. 2025 Feb 3. doi: 10.1111/php.14077.
3
Long-term follow-up of givosiran treatment in patients with acute intermittent porphyria from a phase 1/2, 48-month open-label extension study.

本文引用的文献

1
EXPLORE: A Prospective, Multinational, Natural History Study of Patients with Acute Hepatic Porphyria with Recurrent Attacks.探索:一项针对有反复发作史的急性肝性血卟啉症患者的前瞻性、多中心、自然病史研究。
Hepatology. 2020 May;71(5):1546-1558. doi: 10.1002/hep.30936. Epub 2019 Nov 7.
2
Recent advances on porphyria genetics: Inheritance, penetrance & molecular heterogeneity, including new modifying/causative genes.卟啉症遗传学的最新进展:遗传、外显率和分子异质性,包括新的修饰/致病基因。
Mol Genet Metab. 2019 Nov;128(3):320-331. doi: 10.1016/j.ymgme.2018.11.012. Epub 2018 Nov 30.
3
Porphyria.
急性间歇性血卟啉症患者在一项 1/2 期、48 个月开放标签扩展研究中的吉沃西仑长期治疗随访结果。
Orphanet J Rare Dis. 2024 Oct 3;19(1):365. doi: 10.1186/s13023-024-03284-w.
4
Acute intermittent porphyria: a disease with low penetrance and high heterogeneity.急性间歇性卟啉病:一种外显率低且异质性高的疾病。
Front Genet. 2024 Aug 12;15:1374965. doi: 10.3389/fgene.2024.1374965. eCollection 2024.
5
Elevated homocysteine is negatively correlated with plasma cystathionine β-synthase activity in givosiran-treated patients.在接受givosiran治疗的患者中,同型半胱氨酸水平升高与血浆胱硫醚β-合酶活性呈负相关。
JIMD Rep. 2024 Apr 29;65(4):262-271. doi: 10.1002/jmd2.12416. eCollection 2024 Jul.
6
Preventing hyperhomocysteinemia using vitamin B supplementation in Givosiran-treated acute intermittent porphyria: Highlights from a case report and brief literature review.在接受吉沃西坦治疗的急性间歇性卟啉症中使用维生素B补充剂预防高同型半胱氨酸血症:病例报告及简要文献综述要点
Mol Genet Metab Rep. 2024 Apr 4;39:101076. doi: 10.1016/j.ymgmr.2024.101076. eCollection 2024 Jun.
7
A case report of acute intermittent porphyria leading to severe disability.一例导致严重残疾的急性间歇性卟啉病病例报告。
Front Neurol. 2024 Jan 11;14:1334743. doi: 10.3389/fneur.2023.1334743. eCollection 2023.
8
The diagnosis of acute intermittent porphyria combined with seizures: Case report.急性间歇性血卟啉病合并癫痫发作的诊断:病例报告。
Medicine (Baltimore). 2023 Dec 15;102(50):e36167. doi: 10.1097/MD.0000000000036167.
9
Clinical features of acute attacks, chronic symptoms, and long-term complications among patients with acute hepatic porphyria in Japan: a real-world claims database study.日本急性肝性卟啉症患者急性发作、慢性症状和长期并发症的临床特征:一项真实世界理赔数据库研究。
Orphanet J Rare Dis. 2023 Dec 8;18(1):384. doi: 10.1186/s13023-023-02913-0.
10
Targeting the Liver with Nucleic Acid Therapeutics for the Treatment of Systemic Diseases of Liver Origin.针对肝脏的核酸治疗药物用于治疗肝脏起源的系统性疾病。
Pharmacol Rev. 2023 Dec 15;76(1):49-89. doi: 10.1124/pharmrev.123.000815.
卟啉病
N Engl J Med. 2017 Aug 31;377(9):862-872. doi: 10.1056/NEJMra1608634.
4
A Variant of Peptide Transporter 2 Predicts the Severity of Porphyria-Associated Kidney Disease.肽转运体2的一种变体可预测卟啉症相关肾病的严重程度。
J Am Soc Nephrol. 2017 Jun;28(6):1924-1932. doi: 10.1681/ASN.2016080918. Epub 2016 Dec 28.
5
Experiences and concerns of patients with recurrent attacks of acute hepatic porphyria: A qualitative study.急性肝卟啉症复发患者的经历与担忧:一项定性研究。
Mol Genet Metab. 2016 Nov;119(3):278-283. doi: 10.1016/j.ymgme.2016.08.006. Epub 2016 Aug 24.
6
Acute Intermittent Porphyria: Predicted Pathogenicity of HMBS Variants Indicates Extremely Low Penetrance of the Autosomal Dominant Disease.急性间歇性卟啉症:HMBS基因变异的预测致病性表明常染色体显性疾病的外显率极低。
Hum Mutat. 2016 Nov;37(11):1215-1222. doi: 10.1002/humu.23067. Epub 2016 Sep 5.
7
Acute intermittent porphyria: comorbidity and shared familial risks with schizophrenia and bipolar disorder in Sweden.急性间歇性卟啉症:瑞典的精神分裂症和双相情感障碍的合并症和共同家族风险。
Br J Psychiatry. 2015 Dec;207(6):556-7. doi: 10.1192/bjp.bp.114.157073. Epub 2015 Oct 22.
8
Anthropometric and Quality-of-Life Parameters in Acute Intermittent Porphyria Patients.急性间歇性卟啉病患者的人体测量学和生活质量参数
Medicine (Baltimore). 2015 Jul;94(30):e1023. doi: 10.1097/MD.0000000000001023.
9
Role of delta-aminolevulinic acid in the symptoms of acute porphyria.δ-氨基乙酰丙酸在急性卟啉症症状中的作用。
Am J Med. 2015 Mar;128(3):313-7. doi: 10.1016/j.amjmed.2014.10.026. Epub 2014 Nov 8.
10
Acute porphyrias in the USA: features of 108 subjects from porphyrias consortium.美国的急性卟啉病:来自卟啉病联盟的108名受试者的特征
Am J Med. 2014 Dec;127(12):1233-41. doi: 10.1016/j.amjmed.2014.06.036. Epub 2014 Jul 10.